Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
ForecastedResearch announcementOpportunity RFA-CA-28-001

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

National Institutes of Health · Department of Health and Human Services

At a glance

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) is a forecasted federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). The agency's forecast estimates an application due date of June 4, 2027; forecast dates can change. Individual awards are listed as up to $150K, with about 23 awards expected and $5.4M in total estimated funding. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.394 (Cancer Detection and Diagnosis Research).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

  1. Jul 14, 2026Forecast posted
  2. Jan 15, 2027 (est.)Full notice expectednext date
  3. Jun 4, 2027 (est.)Application deadline
  4. Apr 1, 2028 (est.)Est. award date
Posted
Jul 14, 2026
Est. close date
Jun 4, 2027
Est. award date
Apr 1, 2028
Award floor
Not specified
Award ceiling
$150,000
Est. total funding
$5,400,000
Expected awards
23
Cost sharing
Not required
Funding instrument
Grant
Opportunity category
Discretionary
Fiscal year
FY2028

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses
  • Others (see notice)

Additional information on eligibility (from the notice)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. 

Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. 

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. 

How to apply

0 of 8 done · progress saved in this browser

Assistance Listing

What is an ALN?

Reported obligations under ALN 93.394

Historical data · not a prediction
FY24$541M
FY25$602M
FY26$717M est.
Source: SAM.gov Assistance Listing 93.394. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

IMAT Program Contact
NCI-IMAT@nih.gov
240-255-0917

Quick answers

Is this opportunity open for applications yet?

Not yet. It is a forecast — an agency's advance notice of an expected opportunity. The agency estimates posting the full notice around January 15, 2027. Forecast details and dates can change.

Who is eligible to apply for this opportunity?

The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How much funding is available through this opportunity?

Per the notice, individual awards are listed as up to $150k, total estimated program funding is $5,400,000 and the agency expects to make about 23 awards.

How do I apply for this opportunity?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-CA-28-001), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.